Lada Leyens

486 total citations
19 papers, 307 citations indexed

About

Lada Leyens is a scholar working on Economics and Econometrics, Genetics and Physiology. According to data from OpenAlex, Lada Leyens has authored 19 papers receiving a total of 307 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Economics and Econometrics, 5 papers in Genetics and 4 papers in Physiology. Recurrent topics in Lada Leyens's work include Health Systems, Economic Evaluations, Quality of Life (7 papers), BRCA gene mutations in cancer (5 papers) and Pharmaceutical Economics and Policy (4 papers). Lada Leyens is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (7 papers), BRCA gene mutations in cancer (5 papers) and Pharmaceutical Economics and Policy (4 papers). Lada Leyens collaborates with scholars based in Netherlands, Switzerland and United States. Lada Leyens's co-authors include Angela Brand, Matthias Reumann, Lyubov Zaitseva, Ariberto Fassati, Jane Rasaiyaah, Sam J. Wilson, Peter Cherepanov, Denis Horgan, Jonathan A. Lal and Wolfgang Ballensiefen and has published in prestigious journals such as SHILAP Revista de lepidopterología, European Journal of Cancer and Advances in experimental medicine and biology.

In The Last Decade

Lada Leyens

17 papers receiving 298 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lada Leyens Netherlands 9 105 79 66 50 45 19 307
Frank Mannino United States 8 52 0.5× 46 0.6× 28 0.4× 19 0.4× 35 0.8× 14 366
Cynthia Sung Singapore 12 49 0.5× 37 0.5× 46 0.7× 31 0.6× 137 3.0× 23 536
Farhad Towhidi Iran 13 121 1.2× 39 0.5× 42 0.6× 11 0.2× 16 0.4× 17 535
R Verbrugge Belgium 5 46 0.4× 45 0.6× 104 1.6× 10 0.2× 17 0.4× 7 364
William M. O’Neil Canada 12 77 0.7× 23 0.3× 23 0.3× 10 0.2× 41 0.9× 16 432
Aziz Khan Saudi Arabia 12 70 0.7× 47 0.6× 32 0.5× 4 0.1× 16 0.4× 67 434
Alice Matimba South Africa 15 209 2.0× 41 0.5× 210 3.2× 15 0.3× 57 1.3× 37 784
Guoxing Soon United States 11 22 0.2× 79 1.0× 6 0.1× 29 0.6× 65 1.4× 25 388
George Ayodo Kenya 11 74 0.7× 9 0.1× 54 0.8× 22 0.4× 31 0.7× 45 499
Baldur Magnusson Switzerland 13 91 0.9× 35 0.4× 12 0.2× 9 0.2× 66 1.5× 23 681

Countries citing papers authored by Lada Leyens

Since Specialization
Citations

This map shows the geographic impact of Lada Leyens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lada Leyens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lada Leyens more than expected).

Fields of papers citing papers by Lada Leyens

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lada Leyens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lada Leyens. The network helps show where Lada Leyens may publish in the future.

Co-authorship network of co-authors of Lada Leyens

This figure shows the co-authorship network connecting the top 25 collaborators of Lada Leyens. A scholar is included among the top collaborators of Lada Leyens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lada Leyens. Lada Leyens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Dsouza, Viola Savy, et al.. (2025). Artificial intelligence (AI) in pharmacovigilance: A systematic review on predicting adverse drug reactions (ADR) in hospitalized patients. Research in Social and Administrative Pharmacy. 21(6). 453–462. 7 indexed citations
2.
Dsouza, Viola Savy, et al.. (2025). Employing bibliometrics and natural language processing (NLP) to analyse real-world applications of adverse drug reaction. Exploratory Research in Clinical and Social Pharmacy. 18. 100592–100592.
3.
Leyens, Lada, et al.. (2024). Unlocking the full potential of digital endpoints for decision making: a novel modular evidence concept enabling re-use and advancing collaboration. Expert Review of Pharmacoeconomics & Outcomes Research. 24(6). 731–741. 1 indexed citations
4.
Leyens, Lada, et al.. (2024). Why is the uptake of decentralised elements in clinical trials slower than expected?. 6(9). 20–24. 1 indexed citations
5.
Tourneau, Christophe Le, Fabrice André, Åslaug Helland, et al.. (2023). Modified study designs to expand treatment options in personalised oncology: a multistakeholder view. European Journal of Cancer. 194. 113278–113278. 3 indexed citations
6.
Leyens, Lada, et al.. (2023). Comparison of the Latin America Regulation Landscape and International Reference Health Authorities to Hasten Drug Registration and Clinical Research Applications. Therapeutic Innovation & Regulatory Science. 57(6). 1287–1297. 4 indexed citations
7.
Dsouza, Viola Savy, et al.. (2023). Collaborative clinical trials on infectious disease among the G20 nations using scientometric analysis. Perspectives in Clinical Research. 14(4). 211–212. 3 indexed citations
8.
9.
Crouthamel, Michelle, Robert J. Mather, Luis Garcia‐Gancedo, et al.. (2021). Developing a Novel Measurement of Sleep in Rheumatoid Arthritis: Study Proposal for Approach and Considerations. SHILAP Revista de lepidopterología. 5(3). 191–205. 4 indexed citations
10.
Mählmann, Laura, et al.. (2017). Personalized Medicine: What’s in it for Rare Diseases?. Advances in experimental medicine and biology. 1031. 387–404. 28 indexed citations
11.
Leyens, Lada & Angela Brand. (2016). Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods. Public Health Genomics. 19(3). 187–191. 20 indexed citations
12.
Vozikis, Athanassios, D.N. Cooper, Christina Mitropoulou, et al.. (2016). Test Pricing and Reimbursement in Genomic Medicine: Towards a General Strategy. Public Health Genomics. 19(6). 352–363. 30 indexed citations
13.
Leyens, Lada, Matthias Reumann, Núria Malats, & Angela Brand. (2016). Use of big data for drug development and for public and personal health and care. Genetic Epidemiology. 41(1). 51–60. 28 indexed citations
14.
Leyens, Lada, Étienne Richer, Øyvind Melien, Wolfgang Ballensiefen, & Angela Brand. (2015). Available Tools to Facilitate Early Patient Access to Medicines in the EU and the USA: Analysis of Conditional Approvals and the Implications for Personalized Medicine. Public Health Genomics. 18(5). 249–259. 10 indexed citations
15.
Negrouk, Anastassia, Denis Horgan, Alessandra Gorini, et al.. (2015). Clinical Trials, Data Protection and Patient Empowerment in the Era of the New EU Regulations. Public Health Genomics. 18(6). 386–395. 9 indexed citations
16.
Syme, Rachel, Bruce Carleton, Lada Leyens, & Étienne Richer. (2015). Integrating Personalized Medicine in the Canadian Environment: Efforts Facilitating Oncology Clinical Research. Public Health Genomics. 18(6). 372–380. 5 indexed citations
17.
Horgan, Denis, Marleen E. Jansen, Lada Leyens, et al.. (2014). An Index of Barriers for the Implementation of Personalised Medicine and Pharmacogenomics in Europe. Public Health Genomics. 17(5-6). 287–298. 61 indexed citations
18.
Leyens, Lada, et al.. (2014). Working Towards Personalization in Medicine: Main Obstacles to Reaching this Vision from Today’s Perspective. Personalized Medicine. 11(7). 641–649. 11 indexed citations
19.
Zaitseva, Lyubov, Peter Cherepanov, Lada Leyens, et al.. (2009). HIV-1 exploits importin 7 to maximize nuclear import of its DNA genome. Retrovirology. 6(1). 11–11. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Frank Mannino Breakdown of academic impact, for papers by Cynthia Sung Breakdown of academic impact, for papers by Farhad Towhidi Breakdown of academic impact, for papers by R Verbrugge Breakdown of academic impact, for papers by William M. O’Neil Breakdown of academic impact, for papers by Aziz Khan Breakdown of academic impact, for papers by Alice Matimba Breakdown of academic impact, for papers by Guoxing Soon Breakdown of academic impact, for papers by George Ayodo Breakdown of academic impact, for papers by Baldur Magnusson
Rankless by CCL
2026